- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02900612
Effects of Two Aquatic Training Models in Physiological Parameters of Elderly Dyslipidemic Women.
Effects of Two Aquatic Training Models in Physiological Parameters of Elderly Dyslipidemic Women: a Randomized Controlled Clinical Trial.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
The women will be randomly divided into three groups: water aerobics training (WA), resistance aquatic training (WR) and the third is the control group (who will perform relaxation sessions under water). The three groups will attend classes during 10 weeks, with two weekly sessions of 45 minutes each. The WA and WR groups will use the same four exercises in their training.
The WA group will be trained using the interval method, performing six blocks of five minutes each one, alternating four minutes at intensities corresponding to 90 to 100% of the heart rate corresponding to the second ventilatory threshold (HRVT2) and one minute at intensities between 80 and 90% HRVT2.
The WR group will perform four to eight sets of 20 to 10 seconds along the macrocycle, always at maximal speed execution of the exercises.
Will be measured, before and after the period of 10 weeks of intervention, biochemical, cardiorespiratory, neuromuscular and hemodynamic variables, parameters of quality of life and depressive symptoms in addition to the cardiovascular risk score of the participants of the three groups.
Data will be described by means values and lower and upper limits, with a 95% confidence interval. Comparisons between and within groups were performed using the method of generalized estimates of equations (GEE), with Bonferroni post hoc, adopting a 0.05 significance level.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- being female, aged between 60 and 75, sedentary (not practicing any kind of regular, supervised physical activity in the last three months), have any type of dyslipidemia.
Exclusion Criteria:
- women who are smokers, suffering from cardiovascular disease with associated complications and those with orthopedic diseases that prevented the practice of systematic physical exercise, users of hormone therapy drugs and lipid-lowering medications.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Enkelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: WA (Water Aerobics Training)
Water aerobics training.
|
The WA group will be trained adopting the interval method, performing six blocks of five minutes each one, alternating four minutes at intensities corresponding to 90 to 100% of the heart rate corresponding to the second ventilatory threshold (HRVT2) and one minute at intensities between 80 and 90% HRVT2.
Andre navne:
|
|
Eksperimentel: WR (Water Resistance Training)
Resistance aquatic training.
|
The WR group will perform four to eight sets of 20 to 10 seconds along the macrocycle, always at maximal speed execution of the exercises.
Andre navne:
|
|
Aktiv komparator: CG (Control Group)
Control Group.
|
The control group will perform relaxation classes, including meditation, balance exercises, coordination exercises.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Total Cholesterol (TC) Change
Tidsramme: Change from baseline total cholesterol at 10 weeks
|
This variable will be measured through blood collection after 12 hours fasting.
The analysis will be performed through the enzymatic method using kits Siemens, in automated equipment Advia 1800.
|
Change from baseline total cholesterol at 10 weeks
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Triglycerides (TG) Change
Tidsramme: Change from baseline triglycerides at 10 weeks
|
This variable will be measured through blood collection after 12 hours fasting.
The analysis will be performed through the enzymatic method using kits Siemens, in automated equipment Advia 1800.
|
Change from baseline triglycerides at 10 weeks
|
|
High Density Lipoprotein (HDL) Change
Tidsramme: Change from baseline HDL at 10 weeks
|
This variable will be measured through blood collection after 12 hours fasting.
The analysis will be performed through the enzymatic method using kits Siemens, in automated equipment Advia 1800.
|
Change from baseline HDL at 10 weeks
|
|
C-Reactive Protein (CRP) Change
Tidsramme: Change from baseline C-reactive protein at 10 weeks
|
This variable will be measured through blood collection after 12 hours fasting.
The analysis will be performed through the turbidimetric method in Cobas Mira Plus equipment, with the Biotechnical Kit for ultrasensitive C-reactive protein.
|
Change from baseline C-reactive protein at 10 weeks
|
|
Low Density Lipoprotein (LDL) Change
Tidsramme: Change from baseline LDL at 10 weeks
|
This variable will be estimated by Friedewald equation.
|
Change from baseline LDL at 10 weeks
|
|
Total Cholesterol/High Density Lipoprotein Ratio (TC/HDL ratio) Change
Tidsramme: Change from baseline TC/HDL at 10 weeks
|
This variable will be estimated by the simple division of variables.
|
Change from baseline TC/HDL at 10 weeks
|
|
Peak Oxygen Consumption (VO2peak) Change
Tidsramme: Change from baseline VO2peak at 10 weeks
|
This outcome will be measure through maximal progressive treadmill test, using the portable gas analyser VO2000 equipment.
|
Change from baseline VO2peak at 10 weeks
|
|
Oxygen Consumption at anaerobic threshold (VO2VT2) Change
Tidsramme: Change from baseline VO2VT2 at 10 weeks
|
This outcome will be measure through maximal progressive treadmill test, using the portable gas analyser VO2000 equipment.
|
Change from baseline VO2VT2 at 10 weeks
|
|
Heart Rate at anaerobic threshold (HRVT2) Change
Tidsramme: Change from baseline HRVT2 at 10 weeks
|
This outcome will be measure through maximal progressive treadmill test, using a heart rate monitor (POLAR, FT1).
|
Change from baseline HRVT2 at 10 weeks
|
|
Rest Heart Rate (HRrest) Change
Tidsramme: Change from baseline HRrest at 10 weeks
|
This outcome will be measure using a heart rate monitor (POLAR, FT1).
The participants will remain seated in a quiet and controlled temperature room during 15 minutes prior to measurement of the heart rate.
|
Change from baseline HRrest at 10 weeks
|
|
Lipoprotein Lipase (LPL) Change
Tidsramme: Change from baseline LPL at 10 weeks
|
This variable will be measured through blood collection after 12 hours fasting.
The analysis will be performed using the LPL ELISA kit (Cell Biolabs).
The results will be read in a microplate reader (ELISA).
|
Change from baseline LPL at 10 weeks
|
|
Maximal dynamic muscle strength of knees extensors (MSKE) Change
Tidsramme: Change from baseline MSKE at 10 weeks
|
This outcome will be measured through the one-repetition maximal test (1RM).
|
Change from baseline MSKE at 10 weeks
|
|
Maximal dynamic muscle strength of knees flexors (MSKF) Change
Tidsramme: Change from baseline MSKF at 10 weeks
|
This outcome will be measured through the one-repetition maximal test (1RM).
|
Change from baseline MSKF at 10 weeks
|
|
Maximal dynamic muscle strength of horizontal shoulder flexors (MSHSF) Change
Tidsramme: Change from baseline MSHSF at 10 weeks
|
This outcome will be measured through the one-repetition maximal test (1RM).
|
Change from baseline MSHSF at 10 weeks
|
|
Rest Cardiac Output (COrest) Change
Tidsramme: Change from baseline COrest at 10 weeks
|
This outcome will be measured through Impedance Cardiography (Physioflow Lab-1 equipment).
The participants will remain seated in a quiet and controlled temperature room during 15 minutes prior to measurement of the cardiac output.
|
Change from baseline COrest at 10 weeks
|
|
Rest Stroke Volume (SVrest) Change
Tidsramme: Change from baseline SVrest at 10 weeks
|
This outcome will be measured through Impedance Cardiography (Physioflow Lab-1 equipment).
The participants will remain seated in a quiet and controlled temperature room during 15 minutes prior to measurement of the stroke volume.
|
Change from baseline SVrest at 10 weeks
|
|
Peak Cardiac Output (COpeak) Change
Tidsramme: Change from baseline COpeak at 10 weeks
|
This outcome will be measured through Impedance Cardiography (Physioflow Lab-1 equipment), during a maximal progressive treadmill test.
|
Change from baseline COpeak at 10 weeks
|
|
Peak Stroke Volume (SVpeak) Change
Tidsramme: Change from baseline SVpeak at 10 weeks
|
This outcome will be measured through Impedance Cardiography (Physioflow Lab-1 equipment), during a maximal progressive treadmill test.
|
Change from baseline SVpeak at 10 weeks
|
|
Rest Arterial Systolic Blood Pressure (SBPrest) Change
Tidsramme: Change from baseline SBPrest at 10 weeks
|
This outcome will be measured through blood pressure ambulatory monitor (Meditech, ABPM-04).
The participants will remain seated in a quiet and controlled temperature room during 15 minutes prior to measurement of the arterial systolic blood pressure.
|
Change from baseline SBPrest at 10 weeks
|
|
Rest Arterial Diastolic Blood Pressure (DBPrest) Change
Tidsramme: Change from baseline DBPrest at 10 weeks
|
This outcome will be measured through blood pressure ambulatory monitor (Meditech, ABPM-04).
The participants will remain seated in a quiet and controlled temperature room during 15 minutes prior to measurement of the arterial diastolic blood pressure.
|
Change from baseline DBPrest at 10 weeks
|
|
Cardiovascular Risk Score (CRS) Change
Tidsramme: Change from baseline cardiovascular risk score at 10 weeks
|
The Reynolds Risk Score Instrument will be used to estimate the cardiovascular risk.
|
Change from baseline cardiovascular risk score at 10 weeks
|
|
Quality of Life Change
Tidsramme: Change from baseline quality of life at 10 weeks
|
The quality of life will be estimated using the Whoqol-Bref instrument.
|
Change from baseline quality of life at 10 weeks
|
Samarbejdspartnere og efterforskere
Efterforskere
- Ledende efterforsker: Ricardo Stein, Hospital de Clínicas de Porto Alegre
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 14-0547
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .